Free Trial
NASDAQ:QNTM

Quantum Biopharma 8/6/2025 Earnings Report

Quantum Biopharma logo
$5.28 -0.08 (-1.49%)
Closing price 04:00 PM Eastern
Extended Trading
$5.22 -0.06 (-1.21%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Quantum Biopharma EPS Results

Actual EPS
-$3.23
Consensus EPS
-$0.17
Beat/Miss
Missed by -$3.06
One Year Ago EPS
N/A

Quantum Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.89 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quantum Biopharma Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Quantum Biopharma's next earnings date is estimated for Friday, May 8, 2026, based on past reporting schedules.

Conference Call Resources

Quantum Biopharma Earnings Headlines

Elon’s Biggest Launch Ever: 15x Bigger Than SpaceX
The Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked America's #1 stock picker in 2020. He was mentored by two hedge fund billionaires from the Soros network and trained at Caltech. His readers have had the chance to see gains as high as AMD +8,500%... Nvidia +5,000%... Tesla +3,500%... Palantir +1,000%... and Apple +890%.tc pixel
Quantum BioPharma Provides Corporate Update
Quantum BioPharma Ltd.
See More Quantum Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quantum Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quantum Biopharma and other key companies, straight to your email.

About Quantum Biopharma

Quantum Biopharma (NASDAQ:QNTM) is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

View Quantum Biopharma Profile